Let's face it, investors -- FDA decisions can be confusing.

Delays in particular can be difficult to decipher. They can sometimes signal serious problems that investors need to be wary of, and other times they just mean that the agency needs more time to analyze data. In the following video, our health care analyst Max Macaluso looks at how FDA delays can affect investors, and he draws from recent examples at fledgling orphan drugmaker Raptor Pharmaceutical (NASDAQ:RPTP), Eliquis developers Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), obesity drugmaker VIVUS (NASDAQ:VVUS), and inhalable insulin developer MannKind (NASDAQ:56400P706).